Baculovirus Vector Expression of SARS S-Protein Subunits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for producing and using SARS coronavirus proteins as immunogens or antigens for vaccine development, particularly in addressing the high contagiousness and mortality rate of SARS, and there is a need for reliable diagnostic tests and treatments.
Innovation Solution
The development of a baculovirus expression vector system to clone, express, and purify SARS proteins, such as the S-protein, for use in immunogenic compositions and vaccine production, including combinations with other pathogens like influenza, to generate antibodies and induce immunological responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine development methods are used for SARS, then existing vaccine platforms can be utilized, but the high contagiousness and mortality rate of SARS prevents effective immunity generation
Solution Approach 1:
The patent changes the parameter of immunogen structure by using truncated S-protein sequences (S1 and S2 subunits) instead of full-length S-protein, and by creating fusion proteins with influenza hemagglutinin. This modifies the immunogenic properties to generate effective neutralizing antibodies against SARS while avoiding the harmful effects of the virus itself.
Solution Approach 2:
The patent creates composite vaccine compositions by fusing SARS S-protein sequences with influenza hemagglutinin protein, generating chimeric immunogens that combine properties of both pathogens. This composite approach enables simultaneous protection against SARS and influenza while maintaining vaccine effectiveness.
2Productivity
If SARS proteins are expressed using standard expression systems, then protein production is achieved, but the complexity of viral vector systems and purification requirements increases
Solution Approach 1:
The patent extracts and isolates specific functional domains of the SARS S-protein (S1 and S2 subunits) and expresses them separately using baculovirus infection of insect cells. This extraction approach simplifies the expression system by focusing on specific protein segments rather than the entire viral structure, reducing purification complexity while maintaining immunogenicity.
Solution Approach 2:
The patent uses baculovirus as an intermediary vector system to express SARS proteins in insect cells, which then serve as a mediator for producing the immunogens. This intermediary approach simplifies the overall system by using a well-characterized viral vector that efficiently delivers and expresses the target protein without requiring complex eukaryotic expression systems.
3Adaptability or versatility
If multiple pathogen antigens are combined in a single vaccine composition, then broad immunological protection is achieved, but the complexity of composition formulation increases
Solution Approach 1:
The patent merges SARS S-protein immunogens with influenza hemagglutinin protein into a single vaccine composition. This combining approach achieves broad immunological protection against both SARS and influenza pathogens while using a unified formulation strategy that manages complexity through systematic integration of multiple antigens.
Data Source
AI summary
SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.